Mobile Site ›
Normal View

Test ID: FLUC
5-Flucytosine, Serum

Secondary ID A test code used for billing and in test definitions created prior to November 2011

82741

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Monitoring serum concentration during therapy

 

Evaluating potential toxicity

 

The test may also be useful to evaluate patient compliance

Method Name A short description of the method used to perform the test

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

5-Flucytosine, S

Aliases Lists additional common names for a test, as an aid in searching

5-Flucytosine, Antimicrobial Assay
5-Fluorocytosine
Ancobon (Flucytosine)
Antimicrobial Assay, 5-Flucytosine
Flucytosine (Ancobon)
Fluorocytosine

Specimen Type Describes the specimen type needed for testing

Serum

Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.

Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Specimen Volume: 1 mL

Collection Instructions: 

1. Serum for a peak level should be drawn 1 to 2 hours after oral dose or 30 minutes after intravenous infusion. Trough specimens should be drawn immediately prior to next scheduled dose.

2. Spin down within 2 hours of draw.

Forms: If not ordering electronically, submit a General Request Form (Supply T239) with the specimen.

Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.

0.3 mL

Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected

Hemolysis

Mild OK; Gross reject

Lipemia

Mild OK; Gross reject

Icterus

Mild OK; Gross reject

Other

Whole Blood

Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.

Specimen TypeTemperatureTime
SerumFrozen (preferred)14 days
 Refrigerated 7 days
 Ambient 72 hours

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Flucytosine is a broad-spectrum antifungal agent generally used in combined therapy (often with amphotericin B) for treatment of fungal infections such as cryptococcal meningitis. Concerns with toxicity (bone marrow suppression, hepatic dysfunction) and development of fungal resistance limit use of flucytosine, particularly as a monotherapy. The drug is well-absorbed orally, but can also be administered intravenously (available outside of the United States).

 

There is good correlation between serum concentrations of flucytosine with both efficacy and risk for toxicity. Because of the drug’s short half-life (3-6 hours), therapeutic monitoring is typically performed at peak levels, 1 to 2 hours after an oral dose or 30 minutes after intravenous administration.

 

Flucytosine is eliminated primarily as unmetabolized drug in urine. Patients with renal dysfunction may require dose adjustments or more frequent monitoring to ensure that serum concentrations do not accumulate to excessive levels. Nephrotoxicity associated with use of amphotericin B can affect elimination of flucytosine when the drugs are coadministered.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Therapeutic concentration:

Peak >25.0 mcg/mL (difficult infections may require higher concentrations)

Toxic concentration:

Peak >100.0 mcg/mL

Interpretation Provides information to assist in interpretation of the test results

Most individuals display optimal response to flucytosine when peak serum levels (1-2 hours after oral dosing) are >25.0 mcg/mL. Some infections may require higher concentrations for efficacy. Toxicity is more likely when peak serum concentrations are >100.0 mcg/mL.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test cannot be performed on whole blood. Serum must be separated from cells within 2 hours of draw.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Goodwin ML, Drew RH: Antifungal serum concentration monitoring: an update. J Antimicrobial Chemotherapy 2008;61:17-25    

2. Andes D, Pascual A, Marchetti O: Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrobial Agents Chemotherapy 2009;53(1):24-34

Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.

Tuesday, Thursday, 9 a.m.

Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.

2 days

Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result

8 days

Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location The location of the laboratory that performs the test

Rochester

Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

80299

LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.

Result IDReporting NameLOINC Code
827415-Flucytosine, S3639-2